Skip to main content
NewslettersWatchlist

Quest Pharmatech Inc(QPT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.020
Day High0.025
Open:0.025
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Quest Pharmatech Inc flat on Monday (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (QPT)
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
Newswire.ca
Quest Receives Cash Dividend Payment from OncoQuest
Newswire.ca
Oregovomab Phase III Clinical Study fails futility analysis; Data Safety Monitoring Board Recommends Overall Survival Follow Up for Potential Late Immune Effects and Clinical Benefits
AI-generated - The Globe and Mail
Quest PharmaTech: Top 10 Undervalued Biotechnology Industry Stocks (QPT)
Newswire.ca
Quest PharmaTech Provides Corporate Update
Newswire.ca
Quest PharmaTech Announces Results from AGM
Newswire.ca
Quest PharmaTech Provides Product Development Update
Newswire.ca
Quest PharmaTech Provides Corporate Update
Newswire.ca
Quest PharmaTech Clarifies Agreement in Principle with OQP Bio Inc.
Newswire.ca
Quest PharmaTech Provides Corporate Update
Newswire.ca
Quest PharmaTech Announces Results from AGM
Newswire.ca
Quest PharmaTech Provides Corporate Update
Canada Newswire
Quest Provides Corporate Update
Canada Newswire
Quest Provides Additional Information on OncoQuest Transaction and Announces Delay in Annual Filings
Canada Newswire
Quest PharmaTech Announces Results from its April 28, 2020 AGM

Profile

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.